Sign In
Buy CBAY
$32.48
+0 (+0%)
At Close: Apr 11, 2024
CymaBay Therapeutics Inc (NASDAQ:CBAY) Shares Purchased by State Street Corp
01:38am, Tuesday, 11'th Aug 2020
State Street Corp increased its position in shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) by 0.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and
CymaBay Reports Second Quarter 2020 Financial Results and Provides Corporate Update
08:01pm, Monday, 10'th Aug 2020
FDA lifts all clinical holds on seladelpar Positive topline data announced from ENHANCECompany to reinitiate clinical development of seladelpar for patients with PBCCash sufficient to fund current op
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
Oppenheimer: These 3 “Strong Buy” Stocks Could Double, If Not More
07:31pm, Wednesday, 05'th Aug 2020
The “dog days” of summer are here, but it’s just as busy as ever on the Street. As earnings results continue to roll in, investors will be watching for any update on the next economic stimulus p
H.C. Wainwright Keeps Their Buy Rating on CymaBay Therapeutics (CBAY) - Markets
10:21am, Tuesday, 04'th Aug 2020
H.C. Wainwright analyst Ed Arce maintained a Buy rating on CymaBay Therapeutics (CBAY – Research Report) today and set a
CymaBay Therapeutics (CBAY) Gets a Buy Rating from B.Riley FBR - Markets
04:50am, Tuesday, 04'th Aug 2020
In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on CymaBay Therapeutics (CBAY – Research
CymaBay Therapeutics’ (CBAY) “Buy” Rating Reaffirmed at B. Riley
03:46am, Tuesday, 04'th Aug 2020
CymaBay Therapeutics (NASDAQ:CBAY)‘s stock had its “buy” rating reaffirmed by equities research analysts at B. Riley in a research note issued to investors on Tuesday, TipRanks reports. They cur
CymaBay Therapeutics (NASDAQ:CBAY) Earns Buy Rating from Analysts at Oppenheimer
03:14am, Tuesday, 04'th Aug 2020
Research analysts at Oppenheimer started coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY) in a research note issued on Monday, TipRanks reports. The firm set a “buy” rating and a $12.00 pr
CymaBay Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020
08:01pm, Monday, 03'rd Aug 2020
NEWARK, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic dise
CymaBay Therapeutics (CBAY) Received its Third Buy in a Row - Markets
04:50pm, Monday, 03'rd Aug 2020
After Raymond James and Cantor Fitzgerald gave CymaBay Therapeutics (NASDAQ: CBAY) a Buy rating last month, the company received another
CymaBay Announces Positive Topline Results from ENHANCE for Seladelpar in Patients with Primary Biliary Cholangitis
11:00am, Monday, 03'rd Aug 2020
* The study demonstrated seladelpar to be efficacious, safe and well-tolerated * 78.2% of patients on seladelpar 10 mg versus 12.5% on placebo achieved the primary composite outcome after only 3 mo
CymaBay Therapeutics (NASDAQ:CBAY) Rating Increased to Strong-Buy at Raymond James
06:18am, Monday, 27'th Jul 2020
Raymond James upgraded shares of CymaBay Therapeutics (NASDAQ:CBAY) from an outperform rating to a strong-buy rating in a research note released on Thursday morning, The Fly reports. A number of other
MBX Biosciences Closes $34.6 Million Series A Financing in Rare Endocrine Diseases
12:00am, Monday, 27'th Jul 2020
MBX Biosciences, a drug discovery company focused in rare endocrine diseases, today announced the closing of a $34.6 million Series A financing. The f
FDA Lifts All Clinical Holds on Seladelpar
12:00pm, Thursday, 23'rd Jul 2020
Clinical hold lifted on seladelpar INDs in NASH, PBC and PSC Re-initiating clinical development focusing first on Phase 3 for PBCNEWARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeuti
Mid-Morning Market Update: Markets Down; AT&T Earnings Beat Estimates
12:00am, Thursday, 23'rd Jul 2020
Following the market opening Thursday, the Dow traded down 0.26% to 26,936.51 while the NASDAQ fell 0.11% to 10,692.02. The S&P also fell, dropping 0.04% to 3,274.73.
The U.S...
